Results 171 to 180 of about 123,701 (265)
Glaucoma, a major cause of blindness, involves retinal ganglion cell (RGC) degeneration. This study shows growth hormone‐releasing hormone receptor (GHRHR) deficiency preserves RGC survival and restores vision, unlike activation which only aids survival.
Yan Tong +24 more
wiley +1 more source
Dyslipidemia is associated with monocyte lipid metabolic reprogramming in Guillain-Barré syndrome. [PDF]
Chen Y +7 more
europepmc +1 more source
FGL2‐HDAC11 Drives Immunothrombosis via NETs‐Mediated Endothelial Capillarization in MASLD Fibrosis
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is frequently accompanied by hepatic fibrosis and systemic cardiovascular complications; however, the mechanistic interplay between coagulation abnormalities and disease progression remains poorly defined.
Xitang Li +16 more
wiley +1 more source
Mapping metabolic reprogramming in lung and breast cancer through integrative bioinformatics. [PDF]
Al-Damook N +4 more
europepmc +1 more source
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou +21 more
wiley +1 more source
Metabolic Reprogramming of B Cells in Cancer: Effects of Altered Energetics. [PDF]
Sarkar UA +4 more
europepmc +1 more source
Bone cancer pain and depression share a common origin: astrocytic A2‐to‐A1 transition in the posterior piriform cortex. This phenotypic shift disrupts the ATP–adenosine–A2AR–norepinephrine axis, simultaneously driving nociceptive and affective dysfunction.
Jiang‐Ping Liu +14 more
wiley +1 more source
Metabolic reprogramming as a driver of immune escape in melanoma: implications for immunotherapy. [PDF]
Liang H, Han L, Feng X, Zhang L.
europepmc +1 more source
A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu +17 more
wiley +1 more source
ENO1 as a Central Regulator Linking Metabolic Reprogramming to Tumor Plasticity. [PDF]
Lin TC.
europepmc +1 more source

